6.2 Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

Acute decompensated heart failure (ADHF) is a leading cause of ICU admission, characterized by the sudden or gradual onset of signs and symptoms of heart failure requiring urgent therapy. The primary goals in the ICU are to improve hemodynamics, relieve congestion, optimize organ perfusion, and identify reversible triggers (e.g., ischemia, arrhythmias, non-adherence to medications, infections).

Hemodynamic Profiling

Effective management of ADHF begins with a targeted bedside clinical assessment to classify the patient into one of four hemodynamic profiles. This framework, popularized by Dr. Lynne Stevenson, assesses two parameters:

1. Congestion (Wet vs. Dry): Evaluated by assessing for elevated jugular venous pressure, orthopnea, pulmonary crackles, peripheral edema, ascites, and a third heart sound (S3).
2. Perfusion (Warm vs. Cold): Evaluated by assessing for cool extremities, narrow pulse pressure, altered mental status, declining renal function, and symptomatic hypotension.

The Four Profiles

• Profile I (Warm and Dry): The patient is well-compensated. No evidence of congestion or hypoperfusion. Management involves optimizing chronic oral therapies.
• Profile II (Warm and Wet): The most common presentation of ADHF. The patient has adequate perfusion but significant fluid overload. The primary treatment strategy involves aggressive diuresis and vasodilators.
• Profile III (Cold and Dry): The patient is hypoperfused but not congested. This is relatively rare in primary ADHF and often represents over-diuresis in a chronic heart failure patient. Treatment involves cautious fluid resuscitation and adjustment of heart failure medications.
• Profile IV (Cold and Wet): This represents cardiogenic shock. The patient is both congested and hypoperfused. This is the most dangerous profile, carrying a high mortality rate. Management requires a delicate balance of inotropes, vasopressors, diuresis, and often mechanical circulatory support.

Pharmacological Management

Diuretics

Intravenous loop diuretics (furosemide, bumetanide, torsemide) are the cornerstone of therapy for volume overload (the "wet" profiles). They provide rapid symptomatic relief by reducing preload and inducing diuresis.

• Dosing Strategy: The initial IV dose should be at least equivalent to, but often 2 to 2.5 times higher than, the patient's daily oral maintenance dose.
• Evaluation: Urine output should be monitored strictly. If the diuretic response is inadequate (e.g., < 100-150 mL/hr after the first few hours), the dose of the loop diuretic should be doubled.
• Sequential Nephron Blockade: If diuretic resistance develops, adding a thiazide-type diuretic (like metolazone or chlorothiazide) blocks distal sodium reabsorption and can synergistically enhance diuresis.

Vasodilators

Intravenous vasodilators are excellent adjuncts for patients presenting with severe hypertension, acute pulmonary edema, or severe mitral regurgitation. They rapidly decrease ventricular filling pressures (preload) and systemic vascular resistance (afterload).

• Nitroglycerin: Primarily a venodilator at lower doses, reducing preload. Highly effective for acute pulmonary edema.
• Sodium Nitroprusside: A balanced arterial and venous dilator. Provides profound afterload reduction, which increases forward cardiac output in severe left ventricular dysfunction. Caution is required due to the risk of thiocyanate toxicity, especially in renal impairment.
• Contraindications: Vasodilators should be avoided in patients with symptomatic hypotension, severe aortic stenosis, or those who have recently used phosphodiesterase-5 inhibitors.

Inotropes

Inotropes (milrinone, dobutamine) are indicated for patients in the "Cold" profiles (cardiogenic shock) who show evidence of end-organ hypoperfusion despite adequate filling pressures. They increase cardiac contractility.

• Dobutamine: A synthetic catecholamine with strong beta-1 and mild beta-2/alpha-1 adrenergic activity. Increases contractility and heart rate while generally decreasing systemic vascular resistance.
• Milrinone: A phosphodiesterase-3 (PDE3) inhibitor. It increases contractility and causes significant vasodilation (an "inodilator"). It is less arrhythmogenic than dobutamine and works independently of beta-receptors, making it useful in patients on chronic beta-blocker therapy. However, its vasodilatory properties can cause hypotension, and it is renally cleared.
• Caution: Routine use of inotropes in patients without hypoperfusion is associated with increased mortality due to arrhythmias and increased myocardial oxygen demand.

Advanced Therapies and Mechanical Circulatory Support

When pharmacological therapy fails to restore adequate perfusion in "Cold and Wet" patients, temporary mechanical circulatory support (MCS) must be considered promptly to prevent irreversible multi-organ failure.

• Intra-aortic Balloon Pump (IABP): Provides counterpulsation, inflating during diastole to augment coronary perfusion and deflating just before systole to reduce afterload.
• Impella Devices: Percutaneously inserted microaxial pumps that continuously pull blood from the left ventricle and expel it into the ascending aorta, actively unloading the ventricle and providing forward flow.
• Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO): Provides full cardiopulmonary support. Deoxygenated blood is drained from the venous system, oxygenated externally, and pumped back into the arterial system, bypassing the heart and lungs.

Clinical Scenario

A 72-year-old male with a history of ischemic cardiomyopathy (LVEF 20%) presents to the ED with severe dyspnea, orthopnea, and lower extremity edema. His blood pressure is 160/90 mmHg, heart rate is 105 bpm. On exam, he has elevated JVP to the angle of the jaw, bilateral crackles halfway up his lung fields, and warm extremities. His home diuretic is furosemide 40 mg PO daily.

Management: This patient fits the "Warm and Wet" profile. His perfusion is adequate (warm extremities, normal/high blood pressure), but he is profoundly congested. The most appropriate initial step is the administration of an IV loop diuretic. A reasonable starting dose would be IV furosemide 80 mg (double his home oral dose). Given his elevated blood pressure and severe pulmonary edema, starting a nitroglycerin infusion would also be an excellent adjunctive therapy to rapidly decrease preload and relieve dyspnea.